

1           **Acute beetroot juice supplementation on sympathetic nerve activity: A randomized,**  
2                                   **double-blind, placebo-controlled proof-of-concept study**

3

4

5

Karambir Notay<sup>1</sup>, Anthony V. Incognito<sup>1</sup>, Philip J. Millar<sup>1,2</sup>

6

7   <sup>1</sup> Department of Human Health and Nutritional Sciences, University of Guelph, Guelph, Ontario,

8   Canada

9   <sup>2</sup> Toronto General Research Institute, Toronto General Hospital, Toronto, Ontario, Canada

10

11   Running Title: Acute dietary nitrate on sympathetic activity

12

13   Word Count of Manuscript: 4995

14   Word Count of Abstract: 250

15

16

17

18

19   Address for Correspondence and requests for reprints:

20   Philip J. Millar, PhD

21   ANNU 348A, 50 Stone Road East, Guelph, Ontario, Canada, N1G2W1

22   Telephone: 519-824-4120 x54818

23   Email: pmillar@uoguelph.ca

24

25 **Abstract**

26 Acute dietary nitrate supplementation reduces resting blood pressure in healthy normotensives.  
27 This response is attributed to increased nitric oxide bioavailability and peripheral vasodilation,  
28 though nitric oxide also tonically inhibits central sympathetic outflow. We hypothesized that  
29 acute dietary nitrate ( $\text{NO}_3^-$ ) supplementation using beetroot (BR) juice would reduce blood  
30 pressure and muscle sympathetic nerve activity (MSNA) at rest and during exercise. Fourteen  
31 participants (7 men,  $25 \pm 10$  years) underwent blood pressure and MSNA measurements before  
32 and after (165-180 minutes) ingestion of 70ml high-nitrate ( $\sim 6.4 \text{ mmol NO}_3^-$ ) BR or nitrate-  
33 depleted BR placebo (PL;  $\sim 0.0055 \text{ mmol NO}_3^-$ ) in a double-blind, randomized, crossover design.  
34 Blood pressure and MSNA were also collected during 2 minutes of static handgrip (30%  
35 maximal voluntary contraction). The changes in resting MSNA burst frequency ( $-3 \pm 5$  vs.  $3 \pm 4$   
36 bursts/min,  $p=0.001$ ) and burst incidence ( $-4 \pm 7$  vs.  $4 \pm 5$  bursts/100 heartbeats,  $p=0.002$ ) were  
37 lower following BR vs. PL; whereas systolic ( $-1 \pm 5$  vs.  $2 \pm 5$  mmHg,  $p=0.30$ ) and diastolic blood  
38 pressure ( $4 \pm 5$  vs.  $5 \pm 7$  mmHg,  $p=0.68$ ), and spontaneous arterial sympathetic baroreflex  
39 sensitivity ( $p=0.95$ ) were not different. During static handgrip, the change in MSNA burst  
40 incidence ( $1 \pm 8$  vs.  $8 \pm 9$  bursts/100 heartbeats,  $p=0.04$ ) was lower following BR vs. PL, while  
41 MSNA burst frequency ( $6 \pm 6$  vs.  $11 \pm 10$  bursts/min,  $p=0.11$ ), and systolic ( $11 \pm 7$  vs.  $12 \pm 8$  mmHg,  
42  $p=0.94$ ) and diastolic ( $11 \pm 4$  vs.  $11 \pm 4$  mmHg,  $p=0.60$ ) blood pressure were not different.  
43 Collectively, these data provide proof-of-principle that acute BR supplementation can decrease  
44 central sympathetic outflow at rest and during exercise. Dietary nitrate supplementation may  
45 represent a novel intervention to target exaggerated sympathetic outflow in clinical populations.  
46 **Key Words:** Sympathetic nervous system; Dietary nitrate; Blood pressure; Muscle sympathetic  
47 nerve activity; Exercise

48 **New and Noteworthy**

49 The hemodynamic benefits of dietary nitrate supplementation are attributed to nitric oxide-  
50 mediated peripheral vasodilation. We provide proof-of-concept that acute dietary nitrate  
51 supplementation using beetroot juice can decrease muscle sympathetic outflow at rest and during  
52 exercise in a normotensive population. These results have applications for targeting central  
53 sympathetic over-activation in disease.

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

## 71 **Introduction**

72 Acute and chronic dietary nitrate ( $\text{NO}_3^-$ ) supplementation has been demonstrated to elicit dose-  
73 dependent reductions in resting blood pressure in normotensive and hypertensive populations in  
74 prospective studies (e.g. 13, 21, 22, 25, 47) and meta-analyses (2, 44). These results highlight the  
75 potential therapeutic benefit of targeting the nitrate-nitrite-nitric oxide pathway to increase the  
76 bioavailability of the potent vasodilator, nitric oxide (NO) (27, 28, 47). In contrast to  
77 conventional NO synthesis through the oxidation of L-arginine by nitric oxide synthase (38), this  
78 recently discovered pathway involves conversion of nitrate and nitrite back to bioactive NO  
79 without the need for oxygen. Nitrate and nitrite derive from dietary nitrate ingestion and as  
80 metabolic byproducts of NO oxidation (27, 28, 47). Following consumption and absorption  
81 through the gastrointestinal tract, ~25% of ingested dietary nitrate is taken up by the  
82 enterosalivary circulation where it is reduced to nitrite by facultative anaerobic oral bacteria (27,  
83 28, 47). Swallowed nitrite can be spontaneously decomposed to produce NO and other bioactive  
84 nitrogen oxides in the acidic environment of the stomach, however a large proportion is again  
85 absorbed through the gastrointestinal tract, entering the circulation where it can be reduced to  
86 NO by endogenous nitrite reductases (e.g. deoxyhemoglobin, deoxymyoglobin, molybdenum-  
87 containing enzymes) during physiological and pathological hypoxic conditions (27, 28, 47). As a  
88 result, nitrate and nitrite are now considered to represent important reservoirs for NO production  
89 (1, 14).

90 To date, the most common method of administering dietary nitrate has involved  
91 supplementation with beetroot (BR) juice (2, 13, 32, 44). In young normotensives, acute  
92 ingestion of 250 ml (~5.5 mmol) of BR juice decreased resting systolic blood pressure ( $\Delta$ ~5  
93 mmHg) (22), while supplementation with 500 ml (~22.5 mmol) of BR juice was reported to

94 elicit larger reductions ( $\Delta \sim 10/8$  mmHg) (47). Importantly, the peak hypotensive responses in  
95 both studies occurred  $\sim 3$  hours following ingestion, aligned with the time course of peak plasma  
96 nitrite concentration (22, 47). Similar findings have been reported following daily BR  
97 supplementation for 4 weeks in hypertensives without evidence of tachyphylaxis (21). The  
98 mechanisms responsible for these hypotensive effects have been attributed to the peripheral  
99 vasodilatory actions of increased NO bioavailability (7, 47), as highlighted by an increase in  
100 endothelium-dependent vasodilation (47). However, in addition to its role as a vasodilator, NO  
101 exerts a tonic inhibitory influence on the central regulation of sympathetic outflow (41, 49). The  
102 sympathetic nervous system is known similarly to impact blood pressure and endothelium-  
103 dependent vasodilation (18, 19), however, whether the beneficial effects of dietary nitrate  
104 supplementation are mediated, at least in part, via a neural mechanism has not been studied.

105         Therefore, the purpose of the present investigation was to provide proof-of-concept that  
106 acute dietary nitrate supplementation using BR can modulate central sympathetic outflow. We  
107 hypothesized that compared to a nitrate-depleted BR placebo (PL), acute consumption of high-  
108 nitrate BR juice would reduce resting blood pressure and muscle sympathetic nerve activity  
109 (MSNA). To determine whether changes in MSNA were mediated by peripheral or central  
110 mechanisms we also examined spontaneous arterial sympathetic baroreflex sensitivity.  
111 Additionally, as acute nitrate supplementation can improve human exercise performance (32),  
112 we sought to determine whether the neural effects of BR were present during sympathoexcitation  
113 elicited by static handgrip exercise.

114

115

116

## 117 **Methods**

### 118 **Participants**

119           Twenty healthy men and women (10 men,  $27 \pm 11$  years) were recruited to participate in  
120 the study after providing informed written consent. All participants were normotensive, non-  
121 smoking, in sinus rhythm, free of known cardiovascular or metabolic disease, and not taking any  
122 acute (<3 months) or chronic medications, including birth control or antibiotics. All participants  
123 self-reported not currently or previously engaging in formal nitrate supplementation. Due to the  
124 requirement of oral bacteria to convert dietary nitrate to nitrite (15, 47), participants were  
125 required to abstain from using antibacterial mouthwash 30 days prior to the first visit and for the  
126 duration of the study. Participants were reminded verbally throughout the study to ensure  
127 compliance. All procedures were approved by the University of Guelph Research Ethics Board.

128

### 129 **Study Design and Experimental Protocol**

130           Participants completed a double-blind, randomized, placebo-controlled crossover trial  
131 comparing the effects of 70 ml of high-NO<sub>3</sub><sup>-</sup> (~6.4 mmol) BR or NO<sub>3</sub><sup>-</sup>-depleted (~0.0055 mmol)  
132 PL (James White Drinks Ltd, Suffolk, UK). Prior to testing visits, all participants completed a  
133 familiarization visit to the laboratory (~1 hour) where they underwent detailed verbal and visual  
134 explanations of the study requirements and protocols (e.g. microneurography), and attempted a  
135 practice static handgrip contraction. After this, participants were randomized (1:1) to start (on a  
136 subsequent visit) either BR or PL using a random sequence generator (Random.org) followed by  
137 crossover after a >30 day washout. The 70 ml dose of high-nitrate BR (~6.4 mmol) juice is  
138 considered to be equivalent to ~250 ml (~5.5-6.4 mmol) of regular BR juice (21, 22), while the  
139 PL version is manufactured specifically for research purposes, as described (24), and is

140 indistinguishable in physical appearance and taste. The independent Human Nutraceutical  
141 Research Unit at the University of Guelph maintained study blinding and controlled the  
142 dispensing of BR and PL. The experimental protocol was completed during two identical study  
143 visits conducted at the same time of day ( $\pm 2$  hours) and separated by at least one month. Diet  
144 was not restricted during the course of the study, however, each participant was instructed to  
145 refrain from making any major changes during the course of the study. Prior to each testing visit  
146 participants were asked to abstain from caffeine, alcohol, and strenuous exercise for 24 hours.

147         During each testing visit participants entered the laboratory following voiding, underwent  
148 anthropometric measurements, and were positioned supine on a comfortable bed for the  
149 remainder of the study. Next, participants were asked to perform two handgrip contractions in  
150 their left (non-dominant) hand to establish maximal volitional contraction (MVC) (Lafayette  
151 Instrument, Lafayette, LA). Each contraction lasted  $\sim 3$  seconds and was separated by 30 seconds  
152 of rest and the highest value was taken as MVC. Participants then underwent instrumentation ( $\sim 1$   
153 hour) and a 10 minute acclimatization period before continuous heart rate, blood pressure,  
154 MSNA, as well as discrete minute-to-minute brachial blood pressure data were collected over a  
155 10 minute baseline. Upon completion, participants consumed either BR or PL and remained in  
156 the supine position for three hours. Continuous heart rate, blood pressure, and MSNA, along with  
157 five discrete measurements of brachial blood pressure were sampled 165-180 minutes following  
158 supplementation. This time period was chosen to align with peak hypotensive and plasma nitrite  
159 responses reported previously (13, 22, 46, 47). Immediately following the three hour rest  
160 protocol, participants underwent continuous measurements of heart rate, blood pressure, and  
161 MSNA during a 3 minute resting baseline and 2 minute static handgrip contraction at 30% MVC.  
162

163 **Measurements**

164           Electrocardiography (Lead II) was used to acquire beat-to-beat heart rate (ADInstruments  
165 Pty Ltd, Australia). Respiratory movements were tracked to ensure spontaneous breathing  
166 patterns using a piezoelectric transducer placed around the abdomen (Pneumotrace II, UFA,  
167 Morro Bay, CA). To obtain accurate recordings of blood pressure, discrete left brachial blood  
168 pressure was recorded using an automated sphygmomanometer (BPTru Medical Devices,  
169 Coquitlam, Canada). Continuous beat-to-beat blood pressure was recorded from the right middle  
170 finger using photoelectric plethysmography (Finometer MIDI, Finapres Inc, Netherlands).

171           Postganglionic multi-unit MSNA was measured from the right fibular nerve by  
172 microneurography, as described previously (35, 40). A low-impedance tungsten microelectrode  
173 (2m $\Omega$ ; Frederick Haer, Brunswick, ME) was inserted percutaneously into a motor fascicle and  
174 adjusted until spontaneous multi-unit bursts of sympathetic activity were observed. Muscle  
175 sympathetic activity was confirmed by reflexive increases in response to a breath hold and the  
176 absence of responsiveness to unexpected clapping. The MSNA signal was amplified, band-pass  
177 filtered (0.7-2.0 kHz), rectified, and integrated to obtain the mean voltage multi-unit neurogram  
178 (Nerve Traffic Analyzer, Model 662C-4; Absolute Design and Manufacturing Services, Salon,  
179 IA). The neural signal was monitored both audibly and visually to identify changes in the  
180 recording site throughout the study protocol.

181           All continuous data was digitized and stored with LabChart (PowerLab, ADInstruments,  
182 Colorado Springs, CO). Heart rate, respiration, blood pressure, and the integrated multi-unit  
183 MSNA signal were recorded at a sampling frequency of 1000 Hz, while the raw MSNA signal  
184 was collected at 10,000 Hz.

185



186 **Data Analysis**

187 All data was analyzed and tabled by investigators blinded to intervention allocation.  
188 MSNA was analyzed using custom semi-automated LabView software (National Instruments,  
189 Austin, Texas, USA) (35, 40). MSNA was quantified as burst frequency (bursts/min) and burst  
190 incidence (bursts/100 heartbeats). Total MSNA was not calculated as a result of a singular site  
191 change occurring during 13 of the 28 study visits (BR, n=5; PL, n=8). However, MSNA burst  
192 occurrence exhibits excellent intra-day reproducibility within two or more time points on the  
193 same day (16), justifying the use of MSNA burst frequency and incidence. Time-domain  
194 calculation of spontaneous arterial sympathetic baroreflex sensitivity was completed by assessing  
195 the relationship between diastolic blood pressure (input) and MSNA burst occurrence (output),  
196 as described previously (17, 23). A weighted linear regression line was fit between the likelihood  
197 of a MSNA burst (incidence) within 2 mmHg bins of diastolic blood pressure for each  
198 participant. If the regression line possessed an  $r$  value  $\geq 0.5$ , the slope of the line was taken as  
199 sympathetic baroreflex gain.

200

201 **Statistical Analysis**

202 This study was powered to detect a change in MSNA burst frequency (primary variable).  
203 An *a priori* sample size calculation estimated a required sample of 12 participants assuming a  
204 20% reduction in MSNA burst frequency in a crossover trial with an assigned alpha of 0.05 and  
205 beta of 0.2. Resting baseline variables were compared between BR and PL (and visit 1 vs. visit  
206 2) using two-tailed paired t-tests. Intra-class correlation coefficients were used to evaluate  
207 reliability of resting measures between BR and PL study visits. As recommended to improve  
208 precision and reduce bias in crossover (33) and randomized control trials (4), the effects of BR

209 on neural and hemodynamic variables were examined using an analysis of covariance  
210 (ANCOVA) with the change from baseline ( $\Delta$ ) as the dependent variable and the absolute  
211 baseline value as the covariate. This provides the same statistical result as using the absolute  
212 post-treatment value as the dependent variable. The ANCOVA method compares the effects of  
213 BR and PL on each outcome after correcting for differences in resting (pre-ingestion) or  
214 handgrip (post-ingestion) baseline values. As this method may be limited for testing our  
215 hypothesis during exercise, due to the fact that neural and hemodynamic responses could be  
216 influenced by changes at rest, we also compared the change from the handgrip baseline ( $\Delta$ )  
217 during exercise for each variable using a two-tailed paired t-test. All analyses were performed  
218 using IBM SPSS Statistics 24 (Armonk, New York, USA) with significance defined as  $P < 0.05$ .  
219 All values are presented as mean  $\pm$  SD, unless otherwise stated.

220

## 221 **Results**

222 We recruited 20 participants between July 2015 and April 2016. Three participants were  
223 excluded due to the inability to secure a MSNA recording site during visit 1 and three  
224 participants withdrew from the study before completing visit 2. Complete high-quality  
225 microneurographic recordings were obtained in fourteen participants, though only 11 participants  
226 completed the static handgrip exercise protocol (3 dropouts due to time restrictions). Participant  
227 characteristics are reported in Table 1. Resting baseline heart rate, diastolic blood pressure,  
228 MVC, and MSNA were consistent between BR and PL visits (All  $p > 0.05$ ), while systolic blood  
229 pressure tended to be lower during the PL visit ( $p = 0.04$ ). The inter-test reliability was good-to-  
230 excellent ( $r > 0.6$ ) for all resting baseline variables.

231 The changes in resting MSNA burst frequency ( $-3 \pm 5$  vs.  $3 \pm 4$  bursts/min,  $p = 0.001$ ) and

232 burst incidence ( $-4 \pm 7$  vs.  $4 \pm 5$  bursts/100 heartbeats,  $p=0.002$ ) were lower following BR  
233 compared to PL (Figure 1). In contrast, the changes in resting systolic ( $-1 \pm 5$  vs.  $2 \pm 5$  mmHg,  
234  $p=0.30$ ) and diastolic ( $4 \pm 5$  vs.  $5 \pm 7$  mmHg,  $p=0.68$ ) blood pressure (Figure 1), heart rate ( $0 \pm 4$   
235 vs.  $-1 \pm 4$  bpm,  $p=0.70$ ), and spontaneous arterial sympathetic baroreflex sensitivity ( $0.2 \pm 1.4$  vs.  
236  $0.2 \pm 1.3$  bursts/100 heartbeats/mmHg,  $p=0.95$ ) were not different between BR and PL. No  
237 differences were detected (All  $p>0.05$ ) for any of the parameters when measured during visit 1 or  
238 visit 2 (i.e. no order effects).

239 During static handgrip exercise (Figure 2), the changes in systolic ( $11 \pm 7$  vs.  $12 \pm 8$   
240 mmHg,  $p=0.94$ ) and diastolic ( $11 \pm 4$  vs.  $11 \pm 4$  mmHg,  $p=0.60$ ) blood pressure, heart rate ( $13 \pm$   
241  $10$  vs.  $12 \pm 12$  bpm;  $p=0.75$ ), and MSNA burst frequency ( $6 \pm 6$  vs.  $11 \pm 10$  bursts/min,  $p=0.12$ )  
242 were similar following BR and PL. The change in MSNA burst incidence ( $1 \pm 8$  vs.  $8 \pm 9$   
243 bursts/100 heartbeats,  $p=0.04$ ) was smaller following BR vs. PL. Secondary analyses without  
244 adjusting for baseline as a covariate also found no differences during static handgrip in the  
245 changes in systolic ( $p=0.77$ ) and diastolic ( $p=0.58$ ) blood pressure, and heart rate ( $p=0.72$ ), while  
246 the changes in MSNA burst frequency ( $p=0.04$ ) and burst incidence ( $p=0.01$ ) were smaller  
247 following BR vs. PL.

248

## 249 **Discussion**

250 Supplementation with dietary nitrate has been shown to reduce resting blood pressure (2,  
251 44), a response attributed to the vasodilator actions of increased NO bioavailability (7, 47). The  
252 present study is the first to investigate the effects of acute dietary nitrate supplementation on  
253 peripheral sympathetic outflow. In support of our hypothesis, BR resulted in lower resting  
254 MSNA and attenuated sympathetic responses during static handgrip in healthy young

255 normotensives. The changes in resting MSNA occurred independent of alterations in  
256 spontaneous arterial sympathetic baroreflex sensitivity suggesting a central mechanism of action.  
257 Surprisingly, no differences in blood pressure were detected at rest or during exercise. These  
258 results provide proof-of-concept that dietary nitrate supplementation can modulate central  
259 sympathetic outflow and suggest that the established cardiovascular benefits are likely to involve  
260 a neural contribution.

261         To our knowledge, only one study has examined the effects of dietary nitrate  
262 supplementation on the autonomic nervous system, demonstrating that acute BR consumption  
263 increased time-domain heart rate variability (5), a non-invasive marker of cardiac autonomic  
264 modulation. The effects of dietary nitrate supplementation on direct measures of peripheral  
265 sympathetic activity have not been studied. Our hypothesis for reductions in MSNA was based  
266 on evidence that pharmacological blockade of NO synthase (i.e. decreasing NO bioavailability)  
267 raises central sympathetic outflow independent of changes in arterial pressure (41, 49).  
268 Alternatively, increased NO may also influence sympathetic outflow by modulating peripheral  
269 artery compliance and arterial baroreflex transduction (36, 48). Given that the present study  
270 observed a ~17% difference in post-BR and PL resting MSNA independent of a change in  
271 spontaneous arterial sympathetic baroreflex sensitivity, our findings support a central  
272 sympathoinhibitory action of dietary nitrate. Prior research has demonstrated that exogenous  
273 nitrate or nitrite supplementation has the capacity to cross the blood-brain barrier and increase  
274 NO bioavailability in the central nervous system (20, 42), providing a potential mechanism for  
275 the observed reduction in MSNA. The capacity for BR to exert a central neural effect is  
276 important as many of the benefits of dietary nitrate supplementation on blood pressure (2, 44),

277 endothelium-dependent vasodilation (47), and exercise capacity (32), may be caused similarly by  
278 reductions in neurogenic vasoconstriction (18, 19, 39).

279         Supporting the biological plausibility that BR can exert central sympathoinhibition,  
280 analogous results (i.e. 12-30% reductions in MSNA burst incidence independent of changes in  
281 sympathetic baroreflex sensitivity or blood pressure) have been reported in clinical patients  
282 following lipophilic statin therapy (31, 34). A known pleiotropic benefit of statin therapy is the  
283 upregulation of endothelial NO synthase and increase in endothelium-dependent vasodilation  
284 (26). Work in animal models has established that the autonomic effects of statins are secondary  
285 to NO-mediated reductions in oxidative stress in the rostral ventrolateral medulla (12), the  
286 brainstem region considered the final central relay station to integrate sympathetic outflow which  
287 provides the major excitatory input to sympathetic pre-ganglionic neurons (8).

288         During exercise, acute BR supplementation led to smaller MSNA burst incidence  
289 responses during static handgrip than PL, while secondary analyses found significantly smaller  
290 responses in both MSNA burst frequency and burst incidence. The latter results suggest that a  
291 portion of the benefit BR supplementation has on sympathetic responses during exercise involves  
292 modulation of resting baseline values. Given that BR has been shown to produce ergogenic  
293 effects (32), lower MSNA could be the result of increased static handgrip time-to-failure.  
294 However, an increase in handgrip endurance would be expected to elicit parallel responses in  
295 blood pressure. Similar to our findings at rest, no differences in blood pressure responses were  
296 found during static handgrip between BR and PL. In young healthy individuals MSNA does not  
297 correlate with blood pressure at rest (19), and highlighting the complexity of integrative blood  
298 pressure regulation, discordance in muscle sympathetic outflow and blood pressure responses  
299 during static handgrip exercise have been reported previously in the literature (29, 37). It is

300 important to remember that microneurographic assessments of sympathetic outflow reflect  
301 central discharge, not the quantity of neurovascular transduction. It is also possible that reduced  
302 MSNA occurred in parallel with increased sympathetic outflow to other tissues (e.g. renal) to  
303 maintain systemic blood pressure responses. Nevertheless, reducing sympathetic vasoconstrictor  
304 responses directed at skeletal muscle may permit greater blood flow during exercise and improve  
305 exercise capacity (39).

306         The present results suggest a novel clinical application of dietary nitrate supplementation  
307 as a therapeutic strategy to target sympathetic over-activation characteristic of most  
308 cardiovascular disease states, including primary hypertension and heart failure (3, 9, 10, 35).  
309 Increased MSNA is known to be a significant predictor of mortality in patients with heart failure  
310 (3). Other pathological sequelae of increased norepinephrine include arrhythmogenesis, cardiac  
311 and vascular remodeling, insulin resistance, and sudden cardiac death (3, 30, 43, 50). Further,  
312 some current anti-hypertensive medications used frequently in these populations may actually  
313 increase central sympathetic outflow despite blood pressure reductions due to baroreflex  
314 unloading (11). Without addressing the cause of sympathetic over-activation at the source (i.e.  
315 central) the systemic clinical consequences are not abated. The observation that BR  
316 supplementation is not associated with tachyphylaxis, at least after one month (21), and can  
317 reduce central sympathetic outflow supports future autonomic studies in clinical populations.

318         We acknowledge several limitations in the present study. First, our study recruited a  
319 convenience sample composed of young healthy participants for determining proof-of-concept.  
320 Based on the knowledge that MSNA increases both with age (45) and many cardiovascular  
321 disease states (3, 9, 10, 35), we would hypothesize that BR supplementation would elicit a  
322 greater drop in sympathetic outflow in these populations. Second, prior batch analysis of the

323 commercial BR and PL products has reported mean nitrate and nitrite concentrations [range] for  
324 both BR (Nitrate: 3.5 mmol [2.6-4.4 mmol]; Nitrite: 0.1 mmol [0.05-0.16 mmol]) and PL  
325 (Nitrate: 0.34 mmol [0.05-0.56 mmol]; Nitrite: 0.006 mmol [0.001-0.1 mmol]) (6). The results  
326 confirm the difference between BR and PL but suggest that BR nitrate concentrations may be  
327 lower than reported by the manufacturer. This discrepancy could have contributed to the lack of  
328 change in resting blood pressure (in addition to low normotensive status of our participants),  
329 though hypotensive responses are not universal across the literature, even at higher nitrate doses  
330 (2, 44). Importantly, the present results suggest that the nitrate dose required to modulate blood  
331 pressure and MSNA may not be equivalent. Finally, we did not determine plasma nitrite levels in  
332 our study. The plateau in peak plasma nitrite (between 2-3 hours following consumption) has  
333 been characterized in prior studies with consistent findings (13, 21, 22, 25), though inter-  
334 individual differences in peak nitrite concentration may contribute to between-participant  
335 variability. Future studies are required to examine the dose-response relationships between  
336 changes in plasma nitrite and MSNA.

337         In summary, acute supplementation with beetroot juice decreased resting MSNA and  
338 attenuated muscle sympathetic activation during handgrip exercise. In concert with the findings  
339 of unaltered arterial sympathetic baroreflex sensitivity, these results provide proof-of-concept  
340 that dietary nitrate supplementation can cause central sympathoinhibition in a young healthy  
341 population. Reductions in sympathetic outflow are likely to contribute to the cardiovascular  
342 benefits of dietary nitrate supplementation, while offering a new autonomic restorative  
343 intervention to be tested in future clinical trials in patient groups associated with sympathetic  
344 over-activation (3, 9, 10, 35).

345

346 **Sources of Funding**

347 This research was supported by a Natural Science and Engineering Research Council of Canada  
348 (NSERC) Discovery Grant (P.J.M. #1256447-2015), the Canada Foundation for Innovation  
349 (P.J.M. #34379), and the Ontario Ministry of Research, Innovation, and Science (P.J.M.). A.V.I.  
350 was supported by a CIHR Fredrick Banting and Charles Best Canada Graduate Scholarship.

351

352 **Disclosures**

353 The authors declare no conflicts of interest relevant to the content of this study.

354

355 **Author Contributions**

356 P.J.M. conceived and designed research; K.N., A.V.I., and P.J.M. performed experiments; K.N.,  
357 and A.V.I. analyzed data; K.N., A.V.I., and P.J.M. interpreted results; K.N. prepared figures and  
358 drafted manuscript; K.N., A.V.I., and P.J.M. edited and revised manuscript; K.N., A.V.I., and  
359 P.J.M. approved final version of manuscript.

360

361

362

363

364

365

366

367

368



369 **References**

- 370 1. Ahluwalia A, Gladwin M, Coleman GD, Hord N, Howard G, Kim-Shapiro DB, Lajous M,  
371 Larsen FJ, Lefer DJ, McClure LA, Nolan BT, Pluta R, Schechter A, Wang C-Y, Ward MH,  
372 Harman JL. Dietary Nitrate and the Epidemiology of Cardiovascular Disease: Report From  
373 a National Heart, Lung, and Blood Institute Workshop. *J Am Heart Assoc* 5: e003402,  
374 2016.
- 375 2. Ashor AW, Lara J, Siervo M. Medium-term effects of dietary nitrate supplementation on  
376 systolic and diastolic blood pressure in adults: a systematic review and meta-analysis. *J*  
377 *Hypertens*. (March 17, 2017). doi: 10.1097/HJH.0000000000001305.
- 378 3. Barretto ACP, Santos AC, Munhoz R, Rondon MUPB, Franco FG, Trombetta IC, Roveda F,  
379 de Matos LNJ, Braga AMW, Middlekauff HR, Negrão CE. Increased muscle sympathetic  
380 nerve activity predicts mortality in heart failure patients. *Int J Cardiol* 135: 302–307, 2009.
- 381 4. Bland JM, Altman DG. Best (but oft forgotten) practices: testing for treatment effects in  
382 randomized trials by separate analyses of changes from baseline in each group is a  
383 misleading approach. *Am J Clin Nutr* 102: 991–994, 2015.
- 384 5. Bond V, Curry BH, Adams RG, Asadi MS, Stancil KA, Millis RM, Haddad GE. Effects of  
385 Nitrate Supplementation on Cardiovascular and Autonomic Reactivity in African-American  
386 Females. *ISRN Physiology* 2014: e676235, 2014.
- 387 6. Bondonno CP, Liu AH, Croft KD, Ward NC, Shinde S, Moodley Y, Lundberg JO, Puddey IB,  
388 Woodman RJ, Hodgson JM. Absence of an effect of high nitrate intake from beetroot juice  
389 on blood pressure in treated hypertensive individuals: a randomized controlled trial. *Am J*  
390 *Clin Nutr* 102: 368–375, 2015.
- 391 7. Cosby K, Partovi KS, Crawford JH, Patel RP, Reiter CD, Martyr S, Yang BK, Waclawiw  
392 MA, Zalos G, Xu X, Huang KT, Shields H, Kim-Shapiro DB, Schechter AN, Cannon RO,  
393 Gladwin MT. Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human  
394 circulation. *Nat Med* 9: 1498–1505, 2003.
- 395 8. Dampney RA. The subretrofacial vasomotor nucleus: anatomical, chemical and  
396 pharmacological properties and role in cardiovascular regulation. *Prog Neurobiol* 42: 197–  
397 227, 1994.
- 398 9. Fisher JP, Young CN, Fadel PJ. Central Sympathetic Overactivity: Maladies and Mechanisms.  
399 *Auton Neurosci Basic Clin* 148: 5–15, 2009.
- 400 10. Floras JS, Hara K. Sympathoneural and haemodynamic characteristics of young subjects  
401 with mild essential hypertension. *J Hypertens* 11: 647–655, 1993.
- 402 11. Fu Q, Zhang R, Witkowski S, Arbab-Zadeh A, Prasad A, Okazaki K, Levine BD. Persistent  
403 Sympathetic Activation During Chronic Antihypertensive Therapy. *Hypertension* 45: 513–  
404 521, 2005.

- 405 12. Gao L, Wang W, Zucker IH. Simvastatin inhibits central sympathetic outflow in heart failure  
406 by a NOS mechanism. *J Pharmacol Exp Ther* 326: 278–285, 2008.
- 407 13. Gee LC, Ahluwalia A. Dietary Nitrate Lowers Blood Pressure: Epidemiological, Pre-clinical  
408 Experimental and Clinical Trial Evidence. *Curr Hypertens Rep* 18: 17, 2016.
- 409 14. Gladwin MT, Raat NJH, Shiva S, Dezfulian C, Hogg N, Kim-Shapiro DB, Patel RP. Nitrite  
410 as a vascular endocrine nitric oxide reservoir that contributes to hypoxic signaling,  
411 cytoprotection, and vasodilation. *Am J Physiol Heart Circ Physiol* 291: H2026-2035, 2006.
- 412 15. Govoni M, Jansson EA, Weitzberg E, Lundberg JO. The increase in plasma nitrite after a  
413 dietary nitrate load is markedly attenuated by an antibacterial mouthwash. *Nitric Oxide Biol*  
414 *Chem* 19: 333–337, 2008.
- 415 16. Grassi G, Bolla G, Seravalle G, Turri C, Lanfranchi A, Mancia G. Comparison between  
416 reproducibility and sensitivity of muscle sympathetic nerve traffic and plasma  
417 noradrenaline in man. *Clin Sci* 92: 285–289, 1997.
- 418 17. Hart EC, Joyner MJ, Wallin BG, Karlsson T, Curry TB, Charkoudian N. Baroreflex control  
419 of muscle sympathetic nerve activity: a nonpharmacological measure of baroreflex  
420 sensitivity. *Am J Physiol Heart Circ Physiol* 298: H816–H822, 2010.
- 421 18. Hijmering ML, Stroes ESG, Olijhoek J, Hutten BA, Blankestijn PJ, Rabelink TJ.  
422 Sympathetic activation markedly reduces endothelium-dependent, flow-mediated  
423 vasodilation. *J Am Coll Cardiol* 39: 683–688, 2002.
- 424 19. Joyner MJ, Charkoudian N, Wallin BG. Sympathetic Nervous System and Blood Pressure in  
425 Humans. *Hypertension* 56: 10–16, 2010.
- 426 20. Jung K-H, Chu K, Ko S-Y, Lee S-T, Sinn D-I, Park D-K, Kim J-M, Song E-C, Kim M, Roh  
427 J-K. Early intravenous infusion of sodium nitrite protects brain against in vivo ischemia-  
428 reperfusion injury. *Stroke* 37: 2744–2750, 2006.
- 429 21. Kapil V, Khambata RS, Robertson A, Caulfield MJ, Ahluwalia A. Dietary nitrate provides  
430 sustained blood pressure lowering in hypertensive patients: a randomized, phase 2, double-  
431 blind, placebo-controlled study. *Hypertension* 65: 320–327, 2015.
- 432 22. Kapil V, Milsom AB, Okorie M, Maleki-Toyserkani S, Akram F, Rehman F, Arghandawi S,  
433 Pearl V, Benjamin N, Loukogeorgakis S, Macallister R, Hobbs AJ, Webb AJ, Ahluwalia A.  
434 Inorganic nitrate supplementation lowers blood pressure in humans: role for nitrite-derived  
435 NO. *Hypertension* 56: 274–281, 2010.
- 436 23. Kienbaum P, Karlsson T, Sverrisdottir YB, Elam M, Wallin BG. Two sites for modulation of  
437 human sympathetic activity by arterial baroreceptors? *J Physiol* 531: 861–869, 2001.
- 438 24. Lansley KE, Winyard PG, Fulford J, Vanhatalo A, Bailey SJ, Blackwell JR, DiMenna FJ,  
439 Gilchrist M, Benjamin N, Jones AM. Dietary nitrate supplementation reduces the O<sub>2</sub> cost  
440 of walking and running: a placebo-controlled study. *J Appl Physiol* 110: 591–600, 2011.

- 441 25. Larsen FJ, Ekblom B, Sahlin K, Lundberg JO, Weitzberg E. Effects of dietary nitrate on  
442 blood pressure in healthy volunteers. *N Engl J Med* 355: 2792–2793, 2006.
- 443 26. Liao JK, Laufs U. Pleiotropic effects of statins. *Annu Rev Pharmacol Toxicol* 45: 89–118,  
444 2005.
- 445 27. Lundberg JO, Govoni M. Inorganic nitrate is a possible source for systemic generation of  
446 nitric oxide. *Free Radic Biol Med* 37: 395–400, 2004.
- 447 28. Lundberg JO, Weitzberg E, Gladwin MT. The nitrate-nitrite-nitric oxide pathway in  
448 physiology and therapeutics. *Nat Rev Drug Discov* 7: 156–167, 2008.
- 449 29. Mark AL, Victor RG, Nerhed C, Wallin BG. Microneurographic studies of the mechanisms  
450 of sympathetic nerve responses to static exercise in humans. *Circ Res* 57: 461–469, 1985.
- 451 30. Masuo K, Mikami H, Ogihara T, Tuck ML. Sympathetic nerve hyperactivity precedes  
452 hyperinsulinemia and blood pressure elevation in a young, nonobese Japanese population.  
453 *Am J Hypertens* 10: 77–83, 1997.
- 454 31. McGowan CL, Murai H, Millar PJ, Notarius CF, Morris BL, Floras JS. Simvastatin reduces  
455 sympathetic outflow and augments endothelium-independent dilation in non-  
456 hyperlipidaemic primary hypertension. *Heart* 99: 240–246, 2013.
- 457 32. McMahon NF, Leveritt MD, Pavey TG. The Effect of Dietary Nitrate Supplementation on  
458 Endurance Exercise Performance in Healthy Adults: A Systematic Review and Meta-  
459 Analysis. *Sports Med* 47: 735–756, 2017.
- 460 33. Metcalfe C. The analysis of cross-over trials with baseline measurements. *Stat Med* 29:  
461 3211–3218, 2010.
- 462 34. Millar PJ, Floras JS. Statins and the autonomic nervous system. *Clin Sci* 126: 401–415, 2014.
- 463 35. Millar PJ, Murai H, Floras JS. Paradoxical Muscle Sympathetic Reflex Activation in Human  
464 Heart Failure. *Circulation* 131: 459–468, 2015.
- 465 36. Monahan KD, Dinunno FA, Seals DR, Clevenger CM, Desouza CA, Tanaka H. Age-  
466 associated changes in cardiovagal baroreflex sensitivity are related to central arterial  
467 compliance. *Am J Physiol Heart Circ Physiol* 281: H284–289, 2001.
- 468 37. Monahan KD, Wilson TE, Ray CA. Omega-3 Fatty Acid Supplementation Augments  
469 Sympathetic Nerve Activity Responses to Physiological Stressors in Humans. *Hypertension*  
470 44: 732–738, 2004.
- 471 38. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. *N Engl J Med* 329: 2002–2012,  
472 1993.

- 473 39. Notarius CF, Millar PJ, Murai H, Morris BL, Marzolini S, Oh P, Floras JS. Divergent muscle  
474 sympathetic responses to dynamic leg exercise in heart failure and age-matched healthy  
475 subjects. *J Physiol* 593: 715–722, 2015.
- 476 40. Notay K, Seed JD, Incognito AV, Doherty CJ, Nardone M, Burns MJ, Millar PJ. Validity  
477 and reliability of measuring resting muscle sympathetic nerve activity using short sampling  
478 durations in healthy humans. *J Appl Physiol* 121: 1065–1073, 2016.
- 479 41. Owlya R, Vollenweider L, Trueb L, Sartori C, Lepori M, Nicod P, Scherrer U.  
480 Cardiovascular and Sympathetic Effects of Nitric Oxide Inhibition at Rest and During  
481 Static Exercise in Humans. *Circulation* 96: 3897–3903, 1997.
- 482 42. Pereira C, Ferreira NR, Rocha BS, Barbosa RM, Laranjinha J. The redox interplay between  
483 nitrite and nitric oxide: From the gut to the brain. *Redox Biol* 1: 276–284, 2013.
- 484 43. Schlaich MP, Kaye DM, Lambert E, Sommerville M, Socratous F, Esler MD. Relation  
485 between cardiac sympathetic activity and hypertensive left ventricular hypertrophy.  
486 *Circulation* 108: 560–565, 2003.
- 487 44. Siervo M, Lara J, Ogbonmwan I, Mathers JC. Inorganic nitrate and beetroot juice  
488 supplementation reduces blood pressure in adults: a systematic review and meta-analysis. *J*  
489 *Nutr* 143: 818–826, 2013.
- 490 45. Vallbo ÅB, Hagbarth K-E, Wallin BG. Microneurography: how the technique developed and  
491 its role in the investigation of the sympathetic nervous system. *J Appl Physiol* 96: 1262–  
492 1269, 2004.
- 493 46. van Velzen AG, Sips AJAM, Schothorst RC, Lambers AC, Meulenbelt J. The oral  
494 bioavailability of nitrate from nitrate-rich vegetables in humans. *Toxicol Lett* 181: 177–181,  
495 2008.
- 496 47. Webb AJ, Patel N, Loukogeorgakis S, Okorie M, Aboud Z, Misra S, Rashid R, Miall P,  
497 Deanfield J, Benjamin N, MacAllister R, Hobbs AJ, Ahluwalia A. Acute blood pressure  
498 lowering, vasoprotective, and antiplatelet properties of dietary nitrate via bioconversion to  
499 nitrite. *Hypertension* 51: 784–790, 2008.
- 500 48. Wilkinson IB, Qasem A, McEniery CM, Webb DJ, Avolio AP, Cockcroft JR. Nitric oxide  
501 regulates local arterial distensibility in vivo. *Circulation* 105: 213–217, 2002.
- 502 49. Young CN, Fisher JP, Gallagher KM, Whaley-Connell A, Chaudhary K, Victor RG, Thomas  
503 GD, Fadel PJ. Inhibition of nitric oxide synthase evokes central sympatho-excitation in  
504 healthy humans. *J Physiol* 587: 4977–4986, 2009.
- 505 50. Zipes DP, Rubart M. Neural modulation of cardiac arrhythmias and sudden cardiac death.  
506 *Heart Rhythm* 3: 108–113, 2006.

507

508 **Table 1.** Baseline participant characteristics between placebo (PL) and beetroot (BR)  
 509 supplementation visits (n=14).  
 510

511 Characteristic	PL	BR	ICC
512 Age (years)	25 ± 10	--	--
513 Sex (Male/Female)	7/7	--	--
514 Height (cm)	167 ± 10	167 ± 10	>0.99
515 Weight (kg)	63 ± 9	63 ± 9	>0.99
516 Body mass index (kg/m <sup>2</sup> )	24 ± 6	24 ± 6	>0.99
517 Maximal volitional contraction (kg)	37 ± 15	36 ± 15	0.97
518 Heart rate (bpm)	64 ± 10	64 ± 8	0.88
519 Systolic blood pressure (mmHg)	103 ± 6	106 ± 6*	0.62
520 Diastolic blood pressure (mmHg)	65 ± 7	64 ± 6	0.71
521 MSNA burst frequency (bursts/min)	21 ± 8	23 ± 7	0.76
522 MSNA burst incidence (bursts/100 heartbeats)	34 ± 13	36 ± 10	0.77
523 Sympathetic BRS (bursts/100 heartbeats/mmHg)	-3.9 ± 1.4	-3.9 ± 1.5	0.63

524 Mean ± SD. \*, p<0.05 versus placebo. PL, placebo; BR, beetroot; BRS, baroreflex sensitivity;  
 525 ICC, intra-class correlation coefficient.  
 526  
 527

528

529

530

531

532

533

534

535

536

537

538

539

540 **Figure Legends**

541 **Figure 1.** The change ( $\Delta$ ) in resting systolic blood pressure (A), diastolic blood pressure (B),  
542 MSNA burst frequency (C), and MSNA burst incidence (D) following placebo (PL) or beetroot  
543 (BR) supplementation. Data obtained from 14 participants and expressed as means  $\pm$  SD. P-  
544 values adjusted for resting baseline values.

545

546

547 **Figure 2.** The change ( $\Delta$ ) in systolic blood pressure (A), diastolic blood pressure (B), MSNA  
548 burst frequency (C), and MSNA burst incidence (D) during 30% MVC static handgrip following  
549 placebo (PL) or beetroot (BR) supplementation. Data obtained from 11 participants and  
550 expressed as means  $\pm$  SD. P-values adjusted for handgrip baseline values.

551

552

553

554

555

556

557

558

559

560

561

562

563

564

565

566

567

568

569

570

571

572

573



